American Journal of Cardiology
Volume 108, Issue 11 , Pages 1606-1613, 1 December 2011

Electrocardiographic Features of Sarcomere Mutation Carriers With and Without Clinically Overt Hypertrophic Cardiomyopathy

  • Neal K. Lakdawala, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
  • ,
  • Jens Jakob Thune, MD, PhD

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
  • ,
  • Barry J. Maron, MD

      Affiliations

    • Hypertrophic Cardiomyopathy Center. Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
  • ,
  • Allison L. Cirino, MS, CGC

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
  • ,
  • Ole Havndrup, MD, PhD

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
  • ,
  • Henning Bundgaard, MD, PhD

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
  • ,
  • Michael Christiansen, MD

      Affiliations

    • Department of Clinical Biochemistry, Statens Serum Institut, Copenhagen, Denmark
  • ,
  • Christian M. Carlsen, MD

      Affiliations

    • Department of Cardiology, Bispebjerg Hospital, Copenhagen, Denmark
  • ,
  • Jean-François Dorval, MD

      Affiliations

    • Department of Cardiology, Royal Columbian Hospital, New Westminster, British Columbia, Canada
  • ,
  • Raymond Y. Kwong, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
  • ,
  • Steven D. Colan, MD

      Affiliations

    • Department of Cardiology, Children's Hospital Boston, Boston, Massachusetts
  • ,
  • Lars V. Køber, MD, DMSC

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
  • ,
  • Carolyn Y. Ho, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: (617) 732-5685; fax: (617) 264-5265

Received 26 February 2011; received in revised form 6 July 2011; accepted 6 July 2011. published online 26 September 2011.

In hypertrophic cardiomyopathy (HC), electrocardiographic (ECG) changes have been postulated to be an early marker of disease, detectable in sarcomere mutation carriers when left ventricular (LV) wall thickness is still normal. However, the ECG features of mutation carriers have not been fully characterized. Therefore, we systematically analyzed ECGs in a genotyped HC population to characterize ECG findings in mutation carriers (G+) with and without echocardiographic LV hypertrophy (LVH), and to evaluate the accuracy of ECG findings to differentiate at-risk mutation carriers from genetically unaffected relatives during family screening. The ECG and echocardiographic findings were analyzed from 213 genotyped subjects (76 G+/LVH−, 57 G+/LVH+ overt HC, 80 genetically unaffected controls). Cardiac magnetic resonance imaging was available on a subset. Q waves and repolarization abnormalities (QST) were highly specific (98% specificity) markers for LVH− mutation carriers, present in 25% of G+/LVH− subjects, and 3% of controls (p <0.001). QST ECG abnormalities remained independently predictive of carrying a sarcomere mutation after adjusting for age and impaired relaxation, another distinguishing feature of G+/LVH− subjects (odds ratio 8.4, p = 0.007). Myocardial scar or perfusion abnormalities were not detected on cardiac magnetic resonance imaging in G+/LVH− subjects, irrespective of the ECG features. In overt HC, 75% had Q waves and/or repolarization changes, but <25% demonstrated common isolated voltage criteria for LVH. In conclusion, Q waves and repolarization abnormalities are the most discriminating ECG features of sarcomere mutation carriers with and without LVH. However, owing to the limited sensitivity of ECG and echocardiographic screening, genetic testing is required to definitively identify at-risk family members.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by grant K23 HL078901 from the National Institutes of Health, Bethesda, Maryland (to C.Y.H.), Hearst Foundation, New York, New York (to B.J.M.), and the American College of Cardiology/Merck Research Foundation, Washington, DC (to N.K.L.).

PII: S0002-9149(11)02297-1

doi:10.1016/j.amjcard.2011.07.019

American Journal of Cardiology
Volume 108, Issue 11 , Pages 1606-1613, 1 December 2011